Fosaprepitant Dimeglumine

For adults undergoing chemotherapy, the standard recommended dose of fosaprepitant dimeglumine is 150 mg. This is administered as a single intravenous infusion on Day 1 of the chemotherapy cycle. The infusion should be completed approximately 30 minutes prior to the start of the chemotherapy treatment.

In clinical practice, this 150 mg dose is designed to replace the three-day oral aprepitant dosing schedule. When used with highly emetogenic chemotherapy (HEC), it is typically combined with:

• Dexamethasone: 12 mg orally on Day 1 (30 minutes before chemo), followed by 8 mg orally twice daily on Day 2, and 8 mg twice daily on Days 3 and 4.
• 5-HT3 Antagonist: Such as ondansetron or palonosetron, administered according to standard protocols on Day 1.

Fosaprepitant is approved for pediatric patients from 6 months to 17 years of age. The dosing is weight-based and depends on the emetogenicity of the chemotherapy:

• Pediatric patients 12 to 17 years: 150 mg as a single IV infusion on Day 1.
• Pediatric patients 6 months to less than 12 years (HEC): 4 mg/kg (maximum 150 mg) on Day 1.
• Pediatric patients 6 months to less than 12 years (MEC): 3 mg/kg (maximum 150 mg) on Day 1.

For children, the infusion time is typically longer (up to 60 minutes for younger infants) to ensure safety and monitoring for infusion-site reactions.

Renal Impairment

No dosage adjustment is necessary for patients with renal impairment, including those with end-stage renal disease (ESRD) undergoing hemodialysis. The drug is not significantly cleared by dialysis.

Hepatic Impairment

• Mild to Moderate (Child-Pugh score 5-9): No dosage adjustment is required.
• Severe (Child-Pugh score >9): There is limited clinical data regarding the use of fosaprepitant in patients with severe hepatic impairment. Healthcare providers should exercise caution, as the liver is the primary site of metabolism for the active form of the drug.

Elderly Patients

In clinical trials, no overall differences in safety or effectiveness were observed between patients over 65 and younger patients. Dosage adjustments are generally not required based solely on age, though individual health status should always be considered.

Fosaprepitant is administered only by healthcare professionals in a clinical setting (hospital or infusion center).

• Preparation: The vial is reconstituted and then diluted in 145 mL of 0.9% Sodium Chloride to a final concentration of 1 mg/mL.
• Administration: It is given through an intravenous line over a period of 20 to 30 minutes.
• Compatibility: It should not be mixed with solutions containing divalent cations (like calcium or magnesium), such as Lactated Ringer's Solution, as this can cause precipitation (clumping of the drug).
• Storage: The lyophilized powder is stored in the refrigerator (2°C to 8°C). Once reconstituted, the solution is stable for 24 hours at room temperature.

Because fosaprepitant is administered by a healthcare provider immediately before chemotherapy, a missed dose is unlikely. However, if your chemotherapy session is delayed or rescheduled, the timing of the fosaprepitant infusion must be adjusted accordingly to ensure it is given 30 minutes before the chemotherapy starts. If you believe you missed the dose, notify your oncology team immediately.

In the event of an overdose, there is no specific antidote. Symptoms may include extreme drowsiness or a worsening of side effects like headache. Treatment consists of supportive care and monitoring of vital signs. Because the drug is highly protein-bound, it cannot be removed from the body through dialysis.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your nurse if you feel any pain or burning at the injection site during the infusion.

Side effects of fosaprepitant dimeglumine are often difficult to distinguish from the side effects of the chemotherapy itself. However, the following are frequently reported:

• Infusion Site Reactions: This is the most common side effect unique to the IV form. Patients may experience redness, swelling, or pain at the site where the needle enters the vein. In some cases, this can lead to 'thrombophlebitis' (inflammation of the vein caused by a blood clot).
• Fatigue and Asthenia: A general feeling of tiredness or lack of energy is very common. This usually peaks 2-3 days after administration.
• Diarrhea or Constipation: Changes in bowel habits are frequent, though these are often managed with over-the-counter medications as directed by a doctor.
• Hiccups: Interestingly, NK1 receptor antagonists are known to cause persistent hiccups in a significant minority of patients.

• Dyspepsia (Indigestion): A feeling of fullness or burning in the upper abdomen.
• Anorexia: A temporary loss of appetite, which may be exacerbated by the chemotherapy.
• Headache: Usually mild to moderate and responsive to acetaminophen.
• Increased Liver Enzymes: Small elevations in ALT and AST (liver function tests) may occur but typically return to normal without intervention.

• Neutropenia: A drop in white blood cell counts (though this is much more commonly caused by the chemotherapy).
• Dysuria: Painful or difficult urination.
• Tinnitus: A ringing or buzzing sound in the ears.
• Insomnia: Difficulty falling or staying asleep.

While rare, some side effects require emergency medical care.

> Warning: Stop taking Fosaprepitant Dimeglumine and call your doctor immediately if you experience any of these:

• Anaphylaxis and Hypersensitivity: Symptoms include hives, rash, itching, sudden trouble breathing or swallowing, and swelling of the face, lips, or throat. This can happen during or immediately after the infusion.
• Severe Infusion Site Reactions: If the drug leaks out of the vein into the surrounding tissue (extravasation), it can cause severe tissue damage or necrosis (tissue death). Signs include blistering, severe pain, or skin sloughing.
• Stevens-Johnson Syndrome (SJS): A rare, life-threatening skin reaction that starts with flu-like symptoms followed by a painful rash that spreads and blisters.

Because fosaprepitant is typically used as a single dose per chemotherapy cycle (once every 2-4 weeks), long-term cumulative side effects are rare. However, repeated infusions into the same vein can lead to permanent vein hardening or scarring. There is no evidence that fosaprepitant causes long-term organ damage when used as directed for CINV prevention.

No FDA black box warnings currently exist for fosaprepitant dimeglumine. However, the FDA has issued safety communications regarding the risk of severe infusion site reactions and the potential for significant drug interactions that could lead to toxicity of other medications.

Report any unusual symptoms to your healthcare provider. It is helpful to keep a 'nausea diary' to track when symptoms occur and which side effects are most bothersome, as this helps your oncology team refine your supportive care plan.

Fosaprepitant dimeglumine is a potent medication that requires careful clinical oversight. The most critical safety consideration is its potential to interact with other drugs. Because it is a 'moderate' inhibitor of the CYP3A4 enzyme, it can raise the levels of other drugs in your blood, potentially leading to dangerous toxicity. Conversely, other drugs can lower the effectiveness of fosaprepitant.

No FDA black box warnings for Fosaprepitant Dimeglumine.

• Allergic Reactions / Anaphylaxis: Hypersensitivity reactions, including anaphylactic shock, have been reported. Most reactions occurred during or shortly after the infusion. Patients with a known allergy to polysorbate 80 (an inactive ingredient in the formulation) should not receive this drug.
• Infusion Site Injury: Fosaprepitant is a known irritant. Severe infusion site reactions, including thrombophlebitis and necrosis, have occurred. If possible, avoid infusion into small veins (like those on the back of the hand) and monitor the site closely for signs of leakage (extravasation).
• Hormonal Contraceptives: Fosaprepitant may reduce the efficacy of hormonal birth control (pills, patches, implants). This effect can last for 28 days after the dose. Patients should use a backup non-hormonal contraceptive method (like condoms) during this time.
• Warfarin Interaction: For patients taking warfarin (a blood thinner), fosaprepitant can cause a significant decrease in the INR (a measure of how fast blood clots). This usually occurs 7 to 10 days after the dose and can increase the risk of blood clots.

Your healthcare provider will perform several checks while you are on this medication:

• Liver Function Tests (LFTs): Periodic blood tests to ensure the liver is processing the drug correctly, especially in patients with pre-existing liver disease.
• INR Monitoring: If you are on warfarin, your doctor will likely order an extra blood test about one week after your chemotherapy to check your clotting levels.
• Visual Inspection: Nurses will visually inspect the IV site every few minutes during the infusion to check for redness or swelling.

Fosaprepitant can cause dizziness and fatigue. While these effects are often due to the chemotherapy itself, patients should avoid driving or operating heavy machinery until they know how the medication affects them. It is highly recommended to have someone else drive you home after your infusion.

There is no direct chemical interaction between alcohol and fosaprepitant. However, alcohol can irritate the stomach lining and worsen nausea or dehydration caused by chemotherapy. It is generally advised to avoid alcohol during the days surrounding your chemotherapy treatment.

Fosaprepitant is not a chronic medication; it is given as a single dose per cycle. Therefore, there is no 'withdrawal syndrome' or need for tapering. If you decide to stop receiving fosaprepitant for future cycles, discuss this with your oncologist, as your risk of severe vomiting will significantly increase.

> Important: Discuss all your medical conditions with your healthcare provider before starting Fosaprepitant Dimeglumine. Ensure they have a complete list of every medication you take, including 'as needed' drugs and herbals.

Fosaprepitant must NEVER be used with the following medications due to the risk of life-threatening heart rhythm problems:

• Pimozide: Fosaprepitant significantly increases pimozide levels, which can lead to QT prolongation and Torsades de Pointes (a dangerous heart rhythm).
• Terfenadine / Astemizole: Though largely off the market, these antihistamines interact similarly and are strictly contraindicated.
• Cisapride: Increased levels can cause serious cardiac arrhythmias.

• Dexamethasone and Methylprednisolone: Fosaprepitant increases the blood levels of these steroids. Typically, the dose of oral dexamethasone should be reduced by approximately 50% when given with fosaprepitant.
• Chemotherapy Agents (Docetaxel, Vinblastine, Vincristine): These drugs are metabolized by CYP3A4. Fosaprepitant may increase their concentration, potentially increasing the risk of nerve damage or low white blood cell counts. Your oncologist will monitor for increased chemo toxicity.
• Benzodiazepines (Midazolam, Alprazolam): Fosaprepitant can double the blood levels of these sedatives, leading to extreme sleepiness or respiratory depression.

• Warfarin (Coumadin): As mentioned, fosaprepitant induces the metabolism of S-warfarin. This results in a decrease in warfarin levels, making the blood more likely to clot. Close INR monitoring is required for 2 weeks following each dose.
• Statins (Atorvastatin, Simvastatin): Levels of these cholesterol drugs may increase, slightly raising the risk of muscle pain (myopathy).

Because fosaprepitant is administered intravenously, traditional food interactions affecting absorption are not a concern. However:

• Grapefruit Juice: Grapefruit is a potent CYP3A4 inhibitor. Consuming it while fosaprepitant is in your system could further inhibit drug metabolism, leading to unpredictable levels of other medications you may be taking.

• St. John's Wort: This herbal supplement is a potent 'inducer' of CYP3A4. It can cause the body to clear fosaprepitant/aprepitant too quickly, making it ineffective at preventing nausea.
• CBD/Cannabis: Some studies suggest cannabinoids interact with the CYP system. Since many cancer patients use CBD for nausea, it is vital to discuss this with your doctor to avoid complicating the metabolism of your anti-emetic regimen.

Fosaprepitant does not generally interfere with common laboratory tests, though it may cause transient elevations in liver enzymes (ALT/AST) and blood urea nitrogen (BUN) which could be misinterpreted as organ dysfunction if the timing of the drug administration is not considered.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can change how your body processes this drug.

There are specific scenarios where fosaprepitant dimeglumine must never be used:

1. 1Hypersensitivity: Patients with a known severe allergy to fosaprepitant, aprepitant (the oral form), or any of the inactive ingredients (specifically polysorbate 80) must not receive the drug. Anaphylaxis has been documented.
2. 2Pimozide Co-administration: As a moderate CYP3A4 inhibitor, fosaprepitant can increase pimozide concentrations to toxic levels, risking fatal cardiac arrhythmias. This is an absolute contraindication.

These are conditions where the doctor must weigh the benefits against significant risks:

• Severe Hepatic Impairment: Because the liver is the primary site for converting and clearing the drug, patients with a Child-Pugh score greater than 9 may have unpredictable drug levels. The risk of toxicity may be higher.
• Active Pregnancy: Unless the benefit clearly outweighs the risk to the fetus, doctors may look for alternative anti-emetics due to a lack of robust human safety data.
• Concomitant use of CYP3A4 Inducers: In patients taking long-term rifampin or phenytoin, fosaprepitant may be so significantly weakened that it fails to prevent vomiting, potentially leading to severe dehydration during chemotherapy.

Patients who have had a skin rash, hives, or breathing trouble after taking oral Aprepitant (Emend capsules) are highly likely to have the same reaction to Fosaprepitant. Furthermore, because the IV formulation contains Polysorbate 80, patients who have reacted poorly to other IV drugs containing this stabilizer (such as certain formulations of docetaxel or amiodarone) should be screened carefully for cross-sensitivity.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Fosaprepitant Dimeglumine. Always disclose any previous 'bad reactions' to medications, even if they seemed minor at the time.

Fosaprepitant is classified under a framework where human data is limited. Animal studies using doses much higher than the human equivalent did not show clear evidence of birth defects. However, because Substance P and NK1 receptors play roles in neurological development, use during pregnancy should be limited to cases where the clinical need is certain. There is no data regarding its use in fertility treatments; however, since it interferes with hormonal contraceptives, it is clear the drug interacts with hormonal pathways.

It is not known whether fosaprepitant or its active metabolite, aprepitant, is excreted in human milk. In animal studies (rats), aprepitant was present in milk. Because of the potential for serious adverse reactions in a nursing infant, a decision should be made whether to discontinue nursing or to avoid the drug, taking into account the importance of the drug to the mother.

Fosaprepitant is approved for use in pediatric patients as young as 6 months of age. Clinical trials have shown that the safety profile in children is generally similar to that in adults, with infusion site reactions being slightly more common in the younger cohorts. It is not approved for use in infants under 6 months old due to immature metabolic pathways.

Clinical studies did not identify significant differences in the safety or efficacy of fosaprepitant between patients 65 years and older and younger patients. However, elderly patients are more likely to have decreased hepatic or renal function and are often on multiple other medications (polypharmacy), which increases the risk of drug-interactions. No specific dose adjustment is recommended for the elderly.

No dosage adjustment is necessary for patients with any degree of renal impairment. The drug is not cleared by the kidneys in its active form, and studies in patients with end-stage renal disease (ESRD) showed that the pharmacokinetics were not significantly altered.

• Mild to Moderate: No adjustment needed.
• Severe: Use with caution. The liver's ability to convert the prodrug and subsequently clear the active aprepitant may be compromised, leading to higher-than-intended systemic exposure.

> Important: Special populations require individualized medical assessment. Pediatric and elderly patients should be monitored more frequently during the infusion for signs of distress or site irritation.

Fosaprepitant dimeglumine is an intravenous prodrug that is rapidly converted via hydrolysis by non-specific esterases to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin-1 (NK1) receptors. It has little to no affinity for serotonin (5-HT3), dopamine, or corticosteroid receptors. By blocking the NK1 receptor in the CNS, it inhibits the emetic reflex, particularly the delayed phase associated with chemotherapy.

Aprepitant penetrates the blood-brain barrier and occupies NK1 receptors in the brain. Positron Emission Tomography (PET) studies in humans have shown that a 150 mg IV dose of fosaprepitant results in >90% receptor occupancy in the striatum of the brain, which is maintained for at least 48 hours. This explains why a single dose is effective at preventing nausea for several days.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | >95% (Albumin) |

| Half-life | 9 to 13 hours (Aprepitant) |

| Tmax | End of 20-30 min infusion |

| Metabolism | Rapid conversion to aprepitant; then CYP3A4 |

| Excretion | Fecal 45%, Renal 40% (as metabolites) |

• Molecular Formula: C23H22F7N4O6P · 2(C7H17NO5)
• Molecular Weight: 1004.83 g/mol (dimeglumine salt)
• Solubility: Highly soluble in water.
• Structure: It is a phosphorylated derivative of aprepitant, which enhances its solubility for IV administration. The dimeglumine salt acts as a buffering agent.

Fosaprepitant is a Neurokinin-1 (NK1) Receptor Antagonist. It is often grouped with other 'prepitants' like oral aprepitant, rolapitant, and netupitant. It is a cornerstone of 'Triple Therapy' (NK1 antagonist + 5-HT3 antagonist + Corticosteroid) for emesis prevention.